Pfizer to Seek Emergency Approval for COVID-19 Vaccine

by Colleen Fleiss on Nov 21 2020 11:48 PM

Pfizer to Seek Emergency Approval for COVID-19 Vaccine
Pfizer is moving ahead with the request of asking the US regulators to allow emergency use of its coronavirus vaccine. In the last 10 days the vaccine has shown 95 per cent efficacy in a totality of two data sets.
Unless some nasty surprises turn up, Pfizer's action on Friday could be the first step towards vaccinating the most vulnerable Americans by December end.

Pfizer and another US company, Moderna, have broken all vaccine development speed records in their race for a cure over the last nine months.

US regulators are standing by for the approval process while coronavirus cases are surging to record levels across all the 50 states.

The Vaccines and Related Biological Products Advisory Committee in the US Food and Drug Administration is a key player in how this process rolls along.

Pfizer's submission also includes safety data on approximately 100 children aged 12-15 years.

"Our work to deliver a safe and effective vaccine has never been more urgent," Pfizer CEO Albert Bourla said in a statement.